Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis

Main Article Content

Philip J Mease
Saima Chohan
Ferran J Garcia Fructuoso
Alice B Gottlieb
Richard C Chou
Alan M Mendelsohn
Michael E Luggen

Keywords

Abstract

Abstract not available.

References

1) Ogdie A, et al. Rheum Dis Clin North Am. 2015;41(4):545−68

2) Singh JA, et al. Arthritis Care Res (Hoboken). 2019;71(1):2−29

3) Ogdie A, et al. Curr Rheumatol Rep. 2017;19(4):21

4) Reich K, et al. Lancet. 2017;390(10091):276−88

5) Kopp T, et al. Nature. 2015;521(7551):222−6

6) Taylor W, et al. Arthritis Rheum. 2006;54(8):2665−73.